RAPT Therapeutics | BiotechTV

top of page

RAPT Therapeutics CEO Brian Wong walks us through the company's focus on inflammatory conditions, including a lead clinical program targeting IgE, and a next-generation CCR4 in preclinical development

He describes the lead program, RPT-904, which is designed to have a longer half-life and to be more selective than omalizumab. Plus, the...

Sep 9

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

RAPT Therapeutics CEO Brian Wong walks us through the company's focus on inflammatory conditions, including a lead clinical program targeting IgE, and a next-generation CCR4 in preclinical development

Follow BiotechTV

Sponsors

Sponsor Spotlight